See today's BioWorld Asia
To read the full story, subscribe or sign in.

Hightide raises $107M series C to advance lead metabolic disease program to phase III

Jan. 10, 2023
By Tamra Sami
Hightide Therapeutics Inc. closed a $107 million series C round that will advance multiple global development programs for lead candidate HTD-1801, including a phase III trial in type 2 diabetes.
BioWorld Asia Financings Diabetes Gastrointestinal Series C China